Literature DB >> 7911002

Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.

R H Lekanne Deprez1, A B Bianchi, N A Groen, B R Seizinger, A Hagemeijer, E van Drunen, D Bootsma, J W Koper, C J Avezaat, N Kley.   

Abstract

The gene for the hereditary disorder neurofibromatosis type 2 (NF2), which predisposes for benign CNS tumors such as vestibular schwannomas and meningiomas, has been assigned to chromosome 22 and recently has been isolated. Mutations in the NF2 gene were found in both sporadic meningiomas and vestibular schwannomas. However, so far only 6 of the 16 exons of the gene have been analyzed. In order to extend the analysis of an involvement of the NF2 gene in the sporadic counterparts of these NF2-related tumors, we have used reverse transcriptase-PCR amplification followed by SSCP and DNA sequence analysis to screen for mutations in the coding region of the NF2 gene. Analysis of the NF2 gene transcript in 53 unrelated patients with meningiomas and vestibular schwannomas revealed mutations in 32% of the sporadic meningiomas (n = 44), in 50% of the sporadic vestibular schwannomas (n = 4), in 100% of the tumors found in NF2 patients (n = 2), and in one of three tumors from multiple-meningioma patients. Of the 18 tumors in which a mutation in the NF2 gene transcript was observed and the copy number of chromosome 22 could be established, 14 also showed loss of (parts of) chromosome 22. This suggests that in sporadic meningiomas and NF2-associated tumors the NF2 gene functions as a recessive tumor-suppressor gene. The mutations detected resulted mostly in frameshifts, predicting truncations starting within the N-terminal half of the putative protein.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911002      PMCID: PMC1918179     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  20 in total

1.  One hundred intracranial meningiomas found incidentally at necropsy.

Authors:  M W WOOD; R J WHITE; J W KERNOHAN
Journal:  J Neuropathol Exp Neurol       Date:  1957-07       Impact factor: 3.685

2.  A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; D Teare; V Newton; T Strachan; R Ramsden; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

Review 3.  Messenger RNA degradation in eukaryotes.

Authors:  A B Sachs
Journal:  Cell       Date:  1993-08-13       Impact factor: 41.582

4.  The sensitivity of single-strand conformation polymorphism analysis for the detection of single base substitutions.

Authors:  V C Sheffield; J S Beck; A E Kwitek; D W Sandstrom; E M Stone
Journal:  Genomics       Date:  1993-05       Impact factor: 5.736

5.  Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types.

Authors:  A B Bianchi; T Hara; V Ramesh; J Gao; A J Klein-Szanto; F Morin; A G Menon; J A Trofatter; J F Gusella; B R Seizinger
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

6.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

Authors:  J A Trofatter; M M MacCollin; J L Rutter; J R Murrell; M P Duyao; D M Parry; R Eldridge; N Kley; A G Menon; K Pulaski
Journal:  Cell       Date:  1993-03-12       Impact factor: 41.582

7.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

8.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.

Authors:  G A Rouleau; P Merel; M Lutchman; M Sanson; J Zucman; C Marineau; K Hoang-Xuan; S Demczuk; C Desmaze; B Plougastel
Journal:  Nature       Date:  1993-06-10       Impact factor: 49.962

Review 9.  Constitutional DNA-level aberrations in chromosome 22 in a patient with multiple meningiomas.

Authors:  R H LeKanne Deprez; N A Groen; D Louz; A Hagemeijer; E van Drunen; J W Koper; C J Avezaat; D Bootsma; T H van der Kwast; E C Zwarthoff
Journal:  Genes Chromosomes Cancer       Date:  1994-02       Impact factor: 5.006

10.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.

Authors:  J M Chirgwin; A E Przybyla; R J MacDonald; W J Rutter
Journal:  Biochemistry       Date:  1979-11-27       Impact factor: 3.162

View more
  31 in total

1.  Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas.

Authors:  L R De Vitis; A Tedde; F Vitelli; F Ammannati; P Mennonna; U Bigozzi; E Montali; L Papi
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

2.  Analysis of the neurofibromatosis type 2 gene in different human tumors of neuroectodermal origin.

Authors:  L R De Vitis; A Tedde; F Vitelli; F Ammannati; P Mennonna; P Bono; B Grammatico; P Grammatico; P Radice; U Bigozzi; E Montali; L Papi
Journal:  Hum Genet       Date:  1996-05       Impact factor: 4.132

3.  Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas.

Authors:  M J Pykett; J Landers; D L George
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

4.  Fluorescence-based mutation detection. Single-strand conformation polymorphism analysis (F-SSCP).

Authors:  J S Ellison
Journal:  Mol Biotechnol       Date:  1996-02       Impact factor: 2.695

5.  Epithelial-specific isoforms of protein 4.1R promote adherens junction assembly in maturing epithelia.

Authors:  Shu-Ching Huang; Jia Y Liang; Long V Vu; Faye H Yu; Alexander C Ou; Jennie Park Ou; Henry S Zhang; Kimberly M Burnett; Edward J Benz
Journal:  J Biol Chem       Date:  2019-11-27       Impact factor: 5.157

6.  Eleven novel mutations in the NF2 tumour suppressor gene.

Authors:  D Bourn; G Evans; S Mason; S Tekes; L Trueman; T Strachan
Journal:  Hum Genet       Date:  1995-05       Impact factor: 4.132

7.  Advances in multidisciplinary therapy for meningiomas.

Authors:  Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

8.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas.

Authors:  A B Bianchi; S I Mitsunaga; J Q Cheng; W M Klein; S C Jhanwar; B Seizinger; N Kley; A J Klein-Szanto; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.

Authors:  Maurits de Vries; Inge Briaire-de Bruijn; Anne-Marie Cleton-Jansen; Martijn J A Malessy; Andel G L van der Mey; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2012-12-08       Impact factor: 4.064

10.  Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma.

Authors:  R Wellenreuther; J A Kraus; D Lenartz; A G Menon; J Schramm; D N Louis; V Ramesh; J F Gusella; O D Wiestler; A von Deimling
Journal:  Am J Pathol       Date:  1995-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.